CA2589886A1 - Crystalline forms of a factor xa inhibitor - Google Patents

Crystalline forms of a factor xa inhibitor Download PDF

Info

Publication number
CA2589886A1
CA2589886A1 CA002589886A CA2589886A CA2589886A1 CA 2589886 A1 CA2589886 A1 CA 2589886A1 CA 002589886 A CA002589886 A CA 002589886A CA 2589886 A CA2589886 A CA 2589886A CA 2589886 A1 CA2589886 A1 CA 2589886A1
Authority
CA
Canada
Prior art keywords
ang
crystalline
pyridin
phenyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002589886A
Other languages
English (en)
French (fr)
Inventor
Michael J. Orwat
Mary F. Malley
Roxana F. Schlam
Steven R. Fabian
Bing-Shiou Yang
Victor W. Rosso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2589886A1 publication Critical patent/CA2589886A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002589886A 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor Abandoned CA2589886A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US60/636,387 2004-12-15
US73798505P 2005-11-18 2005-11-18
US60/737,985 2005-11-18
PCT/US2005/045158 WO2006065853A2 (en) 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor

Publications (1)

Publication Number Publication Date
CA2589886A1 true CA2589886A1 (en) 2006-06-22

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002589886A Abandoned CA2589886A1 (en) 2004-12-15 2005-12-14 Crystalline forms of a factor xa inhibitor

Country Status (15)

Country Link
US (2) US7371864B2 (cg-RX-API-DMAC7.html)
EP (1) EP1828187A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008524228A (cg-RX-API-DMAC7.html)
KR (1) KR20070087606A (cg-RX-API-DMAC7.html)
AR (1) AR053990A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005317158A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519331A2 (cg-RX-API-DMAC7.html)
CA (1) CA2589886A1 (cg-RX-API-DMAC7.html)
IL (1) IL183825A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007006919A (cg-RX-API-DMAC7.html)
NO (1) NO20072666L (cg-RX-API-DMAC7.html)
PE (1) PE20060739A1 (cg-RX-API-DMAC7.html)
RU (1) RU2007126770A (cg-RX-API-DMAC7.html)
TW (1) TW200634011A (cg-RX-API-DMAC7.html)
WO (1) WO2006065853A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5588970B2 (ja) 2008-05-27 2014-09-10 ダコ・デンマーク・エー/エス ハイブリダイゼーション組成物及び方法
US9303287B2 (en) * 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002341693B2 (en) * 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7388096B2 (en) * 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
NO20072666L (no) 2007-09-07
JP2008524228A (ja) 2008-07-10
MX2007006919A (es) 2007-06-26
IL183825A0 (en) 2007-09-20
EP1828187A2 (en) 2007-09-05
BRPI0519331A2 (pt) 2009-01-20
WO2006065853A2 (en) 2006-06-22
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
US7371864B2 (en) 2008-05-13
US20080188517A1 (en) 2008-08-07
WO2006065853A3 (en) 2006-08-24
PE20060739A1 (es) 2006-08-16
RU2007126770A (ru) 2009-01-27
AU2005317158A1 (en) 2006-06-22
AR053990A1 (es) 2007-05-30
KR20070087606A (ko) 2007-08-28

Similar Documents

Publication Publication Date Title
AU2013329125B2 (en) Crystalline forms of a factor XIa inhibitor
JP2018024709A (ja) 第Xa因子阻害剤の結晶形態
US20230151010A1 (en) Crystalline forms of (9r, 135s)-13- {4-[5-chloro-2-(4-chloro-1h,2,3- triazol- 1 -yl)phenyl] -6-oxo- 1,6-dihydropyrimidin- 1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15- tetraazatricyclo [ 12.3.1.0 2·6] octadeca- 1(18), 2(6), 4, 14, 16-pentaen-8-one
US20080188517A1 (en) Crystalline forms of a factor xa inhibitor
AU2019374115B8 (en) Crystalline salts of a plasma kallikrein inhibitor
US7388096B2 (en) Crystalline forms of a factor Xa inhibitor
HK1212333B (en) Crystalline forms of a factor xia inhibitor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued